Changes in Hong Kong stocks | Rongchang Biotech (09995) rose by more than 4% at the end of the month and will disclose positive data for the first quarter of Taitaxip Phase III MG

The Zhitong Finance App learned that Rongchang Biotech (09995) has increased by more than 4%, and its stock price has already risen by more than 40% during the month. As of press release, it rose 4.79% to HK$35, with a turnover of HK$345 million.

According to the news, Rongchang Biotech announced that it will release the first quarter results on April 28. In addition, the company recently announced the results of the Chinese Phase 3 trial of taitacept for the treatment of generalized myasthenia gravis (GmG) in the form of an oral report at the American Academy of Neurology (AAN) annual meeting. The data showed that among 114 Chinese patients, 98.1% of patients with myasthenia gravis improved daily activity score (MG-ADL) of at least 3 points after 24 weeks of treatment with titacip, which is of significant clinical significance.

BOC International believes that the Taitaxip GMgIII data is superior to those already listed in competition, and that the commercialization promotion strategy is clear. SPDB International, on the other hand, said that although the positive phase III data brought opportunities for MG commercialization, considering that the inclusion of Taitacip MG indications in medical insurance is expected to be in 2026 or 2027, 2-3 years later than Agamod's entry into health insurance, the bank believes that short-term MG commercialization volumes have yet to be verified.